Alnylam: Positive Outcome of FDA Advisory Committee Meeting on Patisiran

 Cardiovascular and Renal Drugs Advisory Committee Voted 9:3 That the Benefits of Patisiran Outweigh its Risks for the Treatment of the Cardiomyopathy of ATTR Amyloidosis –

– Prescription Drug User Fee Act Target Action Date is October 8, 2023 –

https://finance.yahoo.com/news/alnylam-announces-positive-outcome-fda-205700234.html